CAJ | 학술논문

目的：观察阿托伐他汀对慢性充血性心力衰竭患者脑钠肽(BNP)及超敏C-反应蛋白(hs-CRP)的影响。方法慢性充血性心力衰竭患者60例随机分为用阿托伐他汀组和常规组两组,每组30例。阿托伐他汀组在常规治疗的基础上加用阿托伐他汀10 mg/d,疗程为12周。比较两组治疗前后血清超敏CRP和BNP水平的变化情况。结果治疗12周后,两组中BNP均较治疗前有显著减低(P<0.05),且阿托伐他汀组显著低于常规组[(245.00±76.64)pg/ml VS (356.00±64.63)pg/ml(P<0.05)]。常规组hs-CRP治疗后无显著下降,但阿托伐他汀组hs-CRP较治疗前有显著下降(P<0.05),且阿托伐他汀组与同期常规组相比差异具有统计学意义[(3.70±4.58)mg/L VS (5.36±5.06)mg/L(P<0.05)]。结论慢性充血性心力衰竭患者常规治疗基础上加用阿托伐他汀治疗可以显著减低患者hs-CRP和BNP水平,改善心功能和预后。
목적：관찰아탁벌타정대만성충혈성심력쇠갈환자뇌납태(BNP)급초민C-반응단백(hs-CRP)적영향。방법만성충혈성심력쇠갈환자60례수궤분위용아탁벌타정조화상규조량조,매조30례。아탁벌타정조재상규치료적기출상가용아탁벌타정10 mg/d,료정위12주。비교량조치료전후혈청초민CRP화BNP수평적변화정황。결과치료12주후,량조중BNP균교치료전유현저감저(P<0.05),차아탁벌타정조현저저우상규조[(245.00±76.64)pg/ml VS (356.00±64.63)pg/ml(P<0.05)]。상규조hs-CRP치료후무현저하강,단아탁벌타정조hs-CRP교치료전유현저하강(P<0.05),차아탁벌타정조여동기상규조상비차이구유통계학의의[(3.70±4.58)mg/L VS (5.36±5.06)mg/L(P<0.05)]。결론만성충혈성심력쇠갈환자상규치료기출상가용아탁벌타정치료가이현저감저환자hs-CRP화BNP수평,개선심공능화예후。
Objective To observe the effect of atorvastatin for paients with chronic congestive heart failure (CCHF) on the changes of B-type natriuretic peptide (BNP) and high-sensitivity C-reactive protein (hs-CRP).Methods Patients with CCHF, 60 cases in all, were randomly divided into atorvastatin group and conventional group, and each group contained 30 cases. The atorvastatin group was treated with atorvastatin 10 mg/d along with routine treatment. After 12-week treatment, the changes of BNP and hs-CRP levels were detected and compared between the two groups.Results After the treatment for 12 weeks,the levels of BNP in both groups were significantly decreased, compared with those before treatment (P<0.05), and the levels of BNP in atorvastatin group were significantly lower than those in conventional group [(245.00±76.64)pg/ml VS (356.00±64.63)pg/ml (P<0.05)]. The level of hs-CRP in the conventional group was not obviously changed, but the level of hs-CRP in atorvastatin group was significantly reduced, compared with those before treatment (P<0.05). Moreover, the levels of hs-CRP in atorvastatin group were lower than those in the conventional group, which had statistical significance [(3.70±4.58)mg/L VS (5.36±5.06)mg/L (P<0.05)].Conclusion Atorvastatin along with conventional treatment can improve heart function and prognosis in patients with CCHF and remarkably reduce the levels of BNP and hs-CRP.